Skip to content

Comparison of the application of ultrasound-guided serratus anterior plane block with bupivacaine liposome added to standard bupivacaine and standard bupivacaine alone in breast surgery: A randomized controlled clinical study

Comparison of the application of ultrasound-guided serratus anterior plane block with bupivacaine liposome added to standard bupivacaine and standard bupivacaine alone in breast surgery: A randomized controlled clinical study

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2500111732
Enrollment
Unknown
Registered
2025-11-05
Start date
2025-11-17
Completion date
Unknown
Last updated
2026-03-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None

Interventions

Bupivacaine liposome group (L group):General anesthesia combined with anterior deltoid plane block anesthesia was adopted. The local anesthetic used was bupivacaine liposome.
Bupivacaine group (Group B):General anesthesia combined with anterior deltoid plane block anesthesia was adopted. The local anesthetic was bupivacaine.

Sponsors

Zhongshan Hospital(Xiamen), Fudan University
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
18 Years to 85 Years

Inclusion criteria

Inclusion criteria: 1. Age: 18 to 85 years old 2. Patients undergoing elective modified radical mastectomy for breast cancer 3. Body Mass Index (BMI) between 18 and 32 4. Female gender 5. Subjects voluntarily participating in this clinical study

Exclusion criteria

Exclusion criteria: 1. Hepatic insufficiency 2. Renal insufficiency 3. Central nervous system disorders, psychiatric conditions 4. Infection near the puncture site 5. Coagulation disorders 6. Uncooperative or non-communicative patients 7. History of chronic pain, chronic alcohol consumption, or substance abuse 8. Pregnant women 9. Patients refusing analgesic pumps or presenting with preoperative psychological conditions such as anxiety or depression 10. Patients with allergies to the investigational medicinal product

Design outcomes

Primary

MeasureTime frame
Postoperative 24-hour recovery quality;The time of the patient's first use of the analgesic pump;

Secondary

MeasureTime frame
The cumulative consumption of opioid drugs within 72 hours after the operation;Postoperative resting and active NRS scores;The recovery quality of the patient 48 hours and 72 hours after the operation;The incidence of postoperative nausea and vomiting;Overall benefit of patient pain relief score (OBAS);The patient's sleep quality on the night of the surgery;The occurrence rate of anesthesia-related complications after surgery;The time when the patient first got out of bed to move around;Total length of hospital stay;surgical complications;The occurrence of chronic postoperative pain;

Countries

China

Contacts

Public ContactZhiyao Wang

Zhongshan Hospital, Fudan University; Zhongshan Hospital(Xiamen), Fudan University

zhiyaowang_0313@163.com+86 150 2152 1161

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Apr 3, 2026